1
|
Zecchini V, Paupe V, Herranz-Montoya I, Janssen J, Wortel IMN, Morris JL, Ferguson A, Chowdury SR, Segarra-Mondejar M, Costa ASH, Pereira GC, Tronci L, Young T, Nikitopoulou E, Yang M, Bihary D, Caicci F, Nagashima S, Speed A, Bokea K, Baig Z, Samarajiwa S, Tran M, Mitchell T, Johnson M, Prudent J, Frezza C. Fumarate induces vesicular release of mtDNA to drive innate immunity. Nature 2023; 615:499-506. [PMID: 36890229 PMCID: PMC10017517 DOI: 10.1038/s41586-023-05770-w] [Citation(s) in RCA: 56] [Impact Index Per Article: 56.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 01/30/2023] [Indexed: 03/10/2023]
Abstract
Mutations in fumarate hydratase (FH) cause hereditary leiomyomatosis and renal cell carcinoma1. Loss of FH in the kidney elicits several oncogenic signalling cascades through the accumulation of the oncometabolite fumarate2. However, although the long-term consequences of FH loss have been described, the acute response has not so far been investigated. Here we generated an inducible mouse model to study the chronology of FH loss in the kidney. We show that loss of FH leads to early alterations of mitochondrial morphology and the release of mitochondrial DNA (mtDNA) into the cytosol, where it triggers the activation of the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING)-TANK-binding kinase 1 (TBK1) pathway and stimulates an inflammatory response that is also partially dependent on retinoic-acid-inducible gene I (RIG-I). Mechanistically, we show that this phenotype is mediated by fumarate and occurs selectively through mitochondrial-derived vesicles in a manner that depends on sorting nexin 9 (SNX9). These results reveal that increased levels of intracellular fumarate induce a remodelling of the mitochondrial network and the generation of mitochondrial-derived vesicles, which allows the release of mtDNAin the cytosol and subsequent activation of the innate immune response.
Collapse
Affiliation(s)
- Vincent Zecchini
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
| | - Vincent Paupe
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
| | - Irene Herranz-Montoya
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
- Molecular Oncology Programme, Growth Factors, Nutrients and Cancer Group Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
| | - Joëlle Janssen
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
- Human and Animal Physiology, Wageningen University and Research, Wageningen, The Netherlands
| | - Inge M N Wortel
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
- Department of Data Science, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands
| | - Jordan L Morris
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
| | - Ashley Ferguson
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
| | - Suvagata Roy Chowdury
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
| | - Marc Segarra-Mondejar
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
- CECAD Research Centre, University of Cologne, Cologne, Germany
| | - Ana S H Costa
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
- Matterworks, Somerville, MA, USA
| | - Gonçalo C Pereira
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
| | - Laura Tronci
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
- Cogentech SRL Benefit Corporation, Milan, Italy
| | - Timothy Young
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
| | | | - Ming Yang
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
- CECAD Research Centre, University of Cologne, Cologne, Germany
| | - Dóra Bihary
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
- VIB KU Leuven Center for Cancer Biology, Leuven, Belgium
| | | | - Shun Nagashima
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
- Laboratory of Regenerative Medicine, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
| | - Alyson Speed
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
| | - Kalliopi Bokea
- Department of Surgical Biotechnology, Division of Surgery and Interventional Science, UCL, London, UK
| | - Zara Baig
- Division of Infection and Immunity, Institute of Immunity and Transplantation, UCL, London, UK
| | - Shamith Samarajiwa
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK
| | - Maxine Tran
- Department of Surgical Biotechnology, Division of Surgery and Interventional Science, UCL, London, UK
| | - Thomas Mitchell
- Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK
- Department of Surgery, University of Cambridge, Cambridge, UK
| | - Mark Johnson
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
| | - Julien Prudent
- Medical Research Council Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK.
| | - Christian Frezza
- Medical Research Council Cancer Unit, University of Cambridge, Cambridge, UK.
- CECAD Research Centre, University of Cologne, Cologne, Germany.
| |
Collapse
|
2
|
Chaves-Pérez A, Santos-de-Frutos K, de la Rosa S, Herranz-Montoya I, Perna C, Djouder N. Transit-amplifying cells control R-spondins in the mouse crypt to modulate intestinal stem cell proliferation. J Exp Med 2022; 219:213460. [PMID: 36098959 PMCID: PMC9475298 DOI: 10.1084/jem.20212405] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 06/24/2022] [Accepted: 08/09/2022] [Indexed: 11/04/2022] Open
Abstract
Intestinal epithelium regenerates rapidly through proliferation of intestinal stem cells (ISCs), orchestrated by potent mitogens secreted within the crypt niche. However, mechanisms regulating these mitogenic factors remain largely unknown. Here, we demonstrate that transit-amplifying (TA) cells, marked by unconventional prefoldin RPB5 interactor (URI), control R-spondin production to guide ISC proliferation. Genetic intestinal URI ablation in mice injures TA cells, reducing their survival capacity, leading to an inflamed tissue and subsequently decreasing R-spondin levels, thereby causing ISC quiescence and disruption of intestinal structure. R-spondin supplementation or restoration of R-spondin levels via cell death inhibition by c-MYC elimination or the suppression of inflammation reinstates ISC proliferation in URI-depleted mice. However, selective c-MYC and p53 suppression are required to fully restore TA cell survival and differentiation capacity and preserve complete intestinal architecture. Our data reveal an unexpected role of TA cells, which represent a signaling platform instrumental for controlling inflammatory cues and R-spondin production, essential for maintaining ISC proliferation and tissue regeneration.
Collapse
Affiliation(s)
- Almudena Chaves-Pérez
- Molecular Oncology Programme, Growth Factors, Nutrients and Cancer Group, Centro Nacional Investigaciones Oncológicas, Madrid, Spain
| | - Karla Santos-de-Frutos
- Molecular Oncology Programme, Growth Factors, Nutrients and Cancer Group, Centro Nacional Investigaciones Oncológicas, Madrid, Spain
| | - Sergio de la Rosa
- Molecular Oncology Programme, Growth Factors, Nutrients and Cancer Group, Centro Nacional Investigaciones Oncológicas, Madrid, Spain
| | - Irene Herranz-Montoya
- Molecular Oncology Programme, Growth Factors, Nutrients and Cancer Group, Centro Nacional Investigaciones Oncológicas, Madrid, Spain
| | - Cristian Perna
- Department of Pathology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain
| | - Nabil Djouder
- Molecular Oncology Programme, Growth Factors, Nutrients and Cancer Group, Centro Nacional Investigaciones Oncológicas, Madrid, Spain
| |
Collapse
|
3
|
Abstract
Prefoldins (PFDNs) are evolutionary conserved co-chaperones, initially discovered in archaea but universally present in eukaryotes. PFDNs are prevalently organized into hetero-hexameric complexes. Although they have been overlooked since their discovery and their functions remain elusive, several reports indicate they act as co-chaperones escorting misfolded or non-native proteins to group II chaperonins. Unlike the eukaryotic PFDNs which interact with cytoskeletal components, the archaeal PFDNs can bind and stabilize a wide range of substrates, possibly due to their great structural diversity. The discovery of the unconventional RPB5 interactor (URI) PFDN-like complex (UPC) suggests that PFDNs have versatile functions and are required for different cellular processes, including an important role in cancer. Here, we summarize their functions across different species. Moreover, a comprehensive analysis of PFDNs genomic alterations across cancer types by using large-scale cancer genomic data indicates that PFDNs are a new class of non-mutated proteins significantly overexpressed in some cancer types.
Collapse
Affiliation(s)
- Irene Herranz-Montoya
- Growth Factors, Nutrients and Cancer Group, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid 28029, Spain
| | - Solip Park
- Computational Cancer Genomics Group, Structural Biology Programme, Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid 28029, Spain
| | - Nabil Djouder
- Growth Factors, Nutrients and Cancer Group, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas, CNIO, Madrid 28029, Spain
| |
Collapse
|